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ABSTRACT Glomeruloid hemangiomas were first described by Chan in 
1990 as a cutaneous marker of POEMS syndrome (Polyneuropathy, Or-
ganomegaly, Endocrinopathy, Monoclonal proteinemia, and Skin chang-
es). POEMS syndrome is a multisystem disease with a significant cutane-
ous involvement. Among its manifestations, hemangiomas are common, 
observed in up to one third of the patients, and, although specific, the 
glomeruloid subtype is very rare. The vascular endothelium growth factor 
(VEGF) is an angiogenic stimulation factor, which also induces increased 
systemic vascular permeability. Thus, a scenario of overexpression of VEGF 
can credibly lead to the assumption of an association between cutane-
ous hemangiomas and systemic manifestations, implying prognostic and 
therapeutic considerations and reinforcing the importance of dermato-
logical periodical consultations for these patients. We report the case of 
a patient in whom glomeruloid hemangiomas marked the recurrence of 
POEMS syndrome, occurring before the systemic symptoms.
KEY WORDS: POEMS syndrome, glomeruloid hemangioma, vascular en-
dothelium growth factor, VEGF
INTRODUCTION
The description of a clinical condition that com-
bines peripheral polyneuropathy and monoclo-
nal gammopathy dates back to 1938, when it was 
termed osteosclerotic myeloma and Crown-Fukase 
syndrome. It was only in 1980 that Bardwick estab-
lished the acronym POEMS, encompassing the main 
manifestations of the syndrome: 1. Polyneuropathy; 
2. Organomegaly; 3. Endocrinopathy; 4. Monoclonal 
proteinemia, and 5. Skin changes (1-4).
It is considered a rare entity, with under-re-
searched incidence and prevalence. It affects men 
(2:1) more frequently in the 5th and 6th decade, and 
most cases are described in Japanese patients (5,6).
Its cause is unknown. Some of the manifesta-
tions are associated with tissue and organs infiltra-
tion by monoclonal immunoglobulin, while others 
seem a consequence of increased cytokine produc-
tion. Among them, interleukin 1 beta, interleukin 6, 
tumor necrosis factor-alpha, and vascular endothelial 
growth factor (VEGF) appear to be especially impor-
tant (1,2).
To establish the diagnosis of POEMS syndrome, 
the patient should satisfy both major criteria: poly-
neuropathy and plasmocyte monoclonal gamopa-
thy associated with at least one minor criterion that 
includes osteoclastic lesions, Castelman disease, 
organomegaly (spleen, liver, lymph nodes), volume 
overload (peripheral edema, ascites, pleural effu-
sion), endocrinopathy (thyroid, adrenals, hypophy-
sis, pancreas, gonads, parathyroid), skin alterations 
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(hyperpigmentation, plethora, hemangioma, hyper-
trichosis), and papilledema (1,2). Cutaneous altera-
tions comprise minor criteria but are present very fre-
quently (2), with the most common being: 1. diffuse 
cutaneous hyperpigmentation (85%), 2. hypertricho-
sis (78%), and 3. sclerodermiform cutaneous thicken-
ing (85%) (5).
About a third of patients with POEMS have cuta-
neous hemangiomas. The following subtypes have 
been described: 1. microvenular; 2. rubi nevus or red 
mole; 3. multinucleated cell angiohistiocytomas; 4. 
glomeruloid hemangioma (GH) (5,6).
GH are dome-shaped erythematous-purplish 
papules, usually multiple, prevalent in the trunk 
and proximal region of the upper limbs. They were 
described by Chan et al. in 1990 and were even pro-
posed as a cutaneous marker of POEMS syndrome 
(7,8). Despite being specific for POEMS, they are quite 
rare, occurring in 3% of cases (6). GH can also occur 
outside POEMS syndrome (9).
We present a case of relapsed POEMS syndrome 
after control with a bone marrow transplant six years 
earlier. The first manifestation of the recurrence was 
the appearance of GHs.
CASE REPORT
A 47-year-old woman, hospitalized due to progres-
sive dyspnea with onset 2 months earlier, reported 
symptoms at slightest physical efforts. Concurrently, 
she complained of papular lesions on the trunk, 
which had appeared 4 months earlier with rapid pro-
gression, both in number and size of the lesions. 
The patient was hypertensive and had POEMS 
syndrome for 11 years, with peripheral neuropathy 
associated with monoclonal gammopathy, Castle-
Figure 1A. Erythematous-purplish papule-nodular lesions 
on the face and neck.
Figure 1B. Lesions on the infra-mammary region.
Figure 1C. Lesions on the upper anterior right trunk.
Figure 1D. Close up of lesions on the upper anterior right 
trunk. 
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man’s disease, osteosclerotic lesions, panhypopitu-
itarism, and secondary hyperparathyroidism, without 
any cutaneous manifestations. She had received a 
bone marrow transplant six years ago and had been 
well-controlled.
The present dermatological examination revealed 
erythematous-purplish papule-nodular lesions pre-
dominantly on the trunk, the proximal region of the 
upper limbs, and the cervical region (Figure 1A, Fig-
ure1B, Figure 1C, and Figure 1D).
Other exams confirmed pleural and pericardial ef-
fusion in addition to ascites. Histologic examination 
obtained from an excisional biopsy of one of the le-
sions revealed a dermal lesion formed by small and 
congested capillaries surrounded by a clear sinusoi-
dal-like space, configuring a glomeruloid aspect. (Fig-
ure 2A and Figure 2B)
GH and the effusion syndrome were interpreted 
as relapse of the disease, and chemotherapy was pro-
posed as treatment. Twelve months after onset of che-
motherapy, the patient achieved partial symptomatic 
control, without alteration of the cutaneous picture.
DISCUSSION
POEMS syndrome has an indolent clinical course, 
with an average survival period of 13.8 years. Due 
to being such a rare disease, there is a lack of con-
trolled clinical studies that would allow considering 
any treatment modality the gold standard. Neverthe-
less, at least 75% of patients are benefitted by some 
therapeutic modality. Management of this syndrome 
is usually carried out in the ambit of hemato-oncol-
ogy. Autologous bone marrow transplant as initial 
treatment of the patient is considered a good option, 
especially for young patients with disseminated os-
teosclerotic disease, allowing symptomatic control 
and an increased survival period (2).
In our case, despite the transplant leading to sat-
isfactory control of the disease over six years, it did 
not avert its relapse. Furthermore, in a quite peculiar 
fashion, the first sign of the recurrence appeared on 
the skin. The literature describes that hemangiomas 
in general, including glomeruloid hemangiomas, can 
precede the other signs and symptoms of the syn-
drome, which makes it reasonable to expect this situ-
ation in case of a possible relapse (6).
GH is classified as a benign vascular neoplasia. 
Since its description as a cutaneous marker of POEMS 
syndrome, some authors reported patients with diag-
nosis confirmed by histopathology but without other 
signs of the syndrome, therefore disproving such 
an association. However, those reports were deal-
ing with young patients with a short follow-up pe-
riod, and therefore we believe that further evolution 
in those patients could present with criteria for the 
syndrome. There are GH reports providing evidence 
of other clinical signs up to 6 years in advance (10). 
As in the case of our patient, GH seems to be more 
common in situations of concurrence of POEMS and 
Castleman’s disease (8).
The physiopathology of GH is not yet completely 
understood. Metaloproteinases and VEGF have an es-
Figure 2A. Histopathology – dermal lesion with newly 
formed capillaries delimited by clear vascular space, config-
uring a glomeruloid aspect (hematoxylin and eosin ×40).
Figure 2B. Higher magnification of histopathology (hema-
toxylin and eosin ×100).
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sential role in angiogenesis and neovascularization. 
VEGF is increased in POEMS syndrome. High serum 
levels of VEGF were detected in patients with GH (11), 
and were thus proposed as the core of its pathogen-
esis (8,12).
Interestingly, in view of this etiopathogenic mech-
anism, we can associate, in theory, the almost eruptive 
appearance of cutaneous hemangiomas with the sys-
temic decomposition manifested by the effusion syn-
drome, with respiratory discomfort. Some researches 
already indicated VEGF as inducer of increased sys-
temic vascular permeability, even correlating high 
VEGF levels with clinical deterioration (13). Therefore, 
hypothetically, GHs would be a prelude of VEGF hyper 
expression and could, if it has been identified and in-
terpreted accordingly, predict a prognosis. This could 
influence the therapeutic decision, since antiangio-
genic and anticytokine substances have already been 
used for POEMS syndrome, for instance bevacizumab 
(monoclonal anti-VEGF antibody).
CONCLUSION
With this illustrative case, we have tried to raise 
awareness in all dermatologists regarding this syn-
drome and its skin manifestations, in addition to re-
inforcing the importance of dermatologic follow-up 
in these patients.
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